GENOMIC VISION to Present at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum
12 Novembre 2015 - 5:45PM
Business Wire
Regulatory News:
Genomic Vision (Paris:GV) a French molecular diagnostics company
specializing in the development of diagnostic tests for genetic
diseases and cancers based on molecular combing technology,
announces that Company management will participate at the Canaccord
Genuity 2015 Medical Technology & Diagnostics Forum taking
place on November 19th at the Westin Grand Central Hotel in New
York City. Aaron Bensimon, Ph.D., CEO & President of Genomic
Vision, will deliver the Company’s corporate presentation on
Thursday, November 19th at 11:40 a.m. Eastern Time (5:40 p.m.
CET).
The Company’s presentation will be webcast live on the internet
and can be accessed by visiting the Investor Relations section of
the Company’s website at www.genomicvision.com. A replay of the
webcast will be archived on the Genomic Vision website for 90 days
following the presentation.
ABOUT GENOMIC VISIONFounded in 2004, Genomic Vision is a
molecular diagnostics company specialized in the development of
diagnostic tests for genetic diseases and cancers based on
molecular combing. Using this innovative technology that allows the
direct visualization of individual DNA molecules, Genomic Vision
detects quantitative and qualitative variations in the genome that
are at the origin of numerous serious pathologies. The Company is
developing a solid portfolio of tests that notably target breast
cancer and cancer of the colon. Since 2013, the Company has
marketed the CombHeliX FSHD test for identifying a myopathy that is
difficult to detect, Facio-scapulo-humeral dystrophy (FSHD), in the
United States thanks to a strategic alliance with Quest
Diagnostics, the American leader in diagnostic laboratory tests,
and in France. Genomic Vision has been listed on Compartment C of
Euronext Paris since April 2014.
For further information, please go to www.genomicvision.com
Member of CAC® Mid & Small, CAC®
All-Tradable and EnterNext© PEA-PME 150 indexes
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151112005753/en/
Genomic VisionAaron Bensimon, Tel.: +33 1 49 08 07
50Co-founder, Chairman &
CEOinvestisseurs@genomicvision.comorLHAInvestor Relations
USAnne Marie Fields, Tel.:
212-838-3777SVPafields@lhai.comorNewCapInvestor Relations /
Strategic CommunicationsDušan Orešanský / Emmanuel Huynh, Tel.: +33
1 44 71 94 92gv@newcap.fr
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Goldfield Corp (American Stock Exchange): 0 recent articles
Plus d'articles sur Goldfield